Discontinuation of Automated Engagement Support
| Status: | Terminated |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/10/2018 |
| Start Date: | October 2015 |
| End Date: | December 31, 2017 |
The Chronic Kidney Disease Engagement System is currently in place for 1700 adults receiving
care from Empire Physicians Medical Group (EPMG), an Independent Practice Association located
in Palm Desert, California. The system monitors routine clinical laboratory test results and
send messages to patients and providers when action is indicated, such as when tests are
overdue or results require extra clinical attention. This study will assess what happens to
laboratory results, utilization of laboratory tests, and costs of care when ther system is
discontinued.
care from Empire Physicians Medical Group (EPMG), an Independent Practice Association located
in Palm Desert, California. The system monitors routine clinical laboratory test results and
send messages to patients and providers when action is indicated, such as when tests are
overdue or results require extra clinical attention. This study will assess what happens to
laboratory results, utilization of laboratory tests, and costs of care when ther system is
discontinued.
The Chronic Kidney Disease Engagement System is currently in place for 1700 adults receiving
care from Empire Physicians Medical Group (EPMG), an Independent Practice Association located
in Palm Desert, California. The system monitors routine clinical laboratory test results and
send messages to patients and providers when action is indicated, such as when tests are
overdue or results require extra clinical attention. Patients receive first class letters
directing them to call their provider. Providers receive fax or electronic messages directing
them to reach out to the patient to arrange follow-up care. It has been used for over three
years and appears to have improved adherence to Chronic Kidney Disease (CKD) treatment
guidelines by influencing both patient and provider actions. EPMG wishes to restrict the
service to those patients with advanced CKD and discontinue it for CKD stages 1-3. The
investigators propose implementing this new policy in a randomized fashion with one half of
the current early stage patients continuing to receive the service while the other half will
no longer receive messages. The investigators will monitor laboratory results and health care
utilization for both groups to determine what effect, if any, discontinuation has on quality
of care.
Human subjects will either continue to receive letters from the service when their tests are
overdue or require additional clinical attention, or will no longer receive the service. All
subjects will continue to receive care from their providers. The main outcomes include the
frequency of recommended tests for CKD, the level of those tests, and utilization of health
care services as indicated by claims data provided by EPMG. No additional data collection
will occur beyond that which has been routinely done for clinical care. The study will
continue for 36 months.
care from Empire Physicians Medical Group (EPMG), an Independent Practice Association located
in Palm Desert, California. The system monitors routine clinical laboratory test results and
send messages to patients and providers when action is indicated, such as when tests are
overdue or results require extra clinical attention. Patients receive first class letters
directing them to call their provider. Providers receive fax or electronic messages directing
them to reach out to the patient to arrange follow-up care. It has been used for over three
years and appears to have improved adherence to Chronic Kidney Disease (CKD) treatment
guidelines by influencing both patient and provider actions. EPMG wishes to restrict the
service to those patients with advanced CKD and discontinue it for CKD stages 1-3. The
investigators propose implementing this new policy in a randomized fashion with one half of
the current early stage patients continuing to receive the service while the other half will
no longer receive messages. The investigators will monitor laboratory results and health care
utilization for both groups to determine what effect, if any, discontinuation has on quality
of care.
Human subjects will either continue to receive letters from the service when their tests are
overdue or require additional clinical attention, or will no longer receive the service. All
subjects will continue to receive care from their providers. The main outcomes include the
frequency of recommended tests for CKD, the level of those tests, and utilization of health
care services as indicated by claims data provided by EPMG. No additional data collection
will occur beyond that which has been routinely done for clinical care. The study will
continue for 36 months.
Inclusion Criteria:
Receiving services from Patient Engagement Services at randomization. CKD Stages 1, 2 or 3.
Under the care of Empire Physicians Medical Group of Palm Desert, California.
Exclusion Criteria:
Patient refusal.
We found this trial at
1
site
Click here to add this to my saved trials
